Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer. 2016/06/17 This issue of [...] Chang Lisa 2018-06-04T17:51:02+00:00 June 18th, 2016|News|Read More
TaiRx’s oral cancer drug with a promising forecast. 2016/3/28 […] Chang Lisa 2021-02-17T15:02:16+00:00 March 28th, 2016|News|Read More
23 major pharmaceutical companies attended the cross-strait new drug discussion panel. 2016/3/18 […] Chang Lisa 2021-02-17T14:59:11+00:00 March 18th, 2016|News|Read More
TaiRx receives Honorable recognition at the 12th Taiwan National Innovation Award. 2015/12/24 […] Chang Lisa 2021-02-17T11:19:32+00:00 December 24th, 2015|News|Read More
TaiRx received Honorable award at the 2015 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award Competition. 2015/9/24 […] Chang Lisa 2021-02-17T13:44:45+00:00 September 24th, 2015|News|Read More
